Uric Acid and Prevalence of Hypertension in a General Population of Japanese: ISSA-CKD Study.
Hypertension, Japanese
Serum uric acid
Journal
Journal of clinical medicine research
ISSN: 1918-3003
Titre abrégé: J Clin Med Res
Pays: Canada
ID NLM: 101538301
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
18
04
2020
accepted:
04
06
2020
entrez:
14
7
2020
pubmed:
14
7
2020
medline:
14
7
2020
Statut:
ppublish
Résumé
There is uncertainty surrounding the causal relationship between serum uric acid and hypertension. The aim was to investigate the association between serum uric acid and prevalence of hypertension in a general population of Japanese. This was a population-based cross-sectional study using health check-up data of the residents of the Iki City, Nagasaki Prefecture, Japan. A total of 7,484 participants aged 30 years or older were included in this study. Serum uric acid was classified into four groups: group 1 (< 357 µmol/L (< 6 mg/dL)), group 2 (357 - 415 µmol/L (6 - 6.9 mg/dL)), group 3 (416 - 475 µmol/L (7 - 7.9 mg/dL)) and group 4 (≥ 476 µmol/L (≥ 8 mg/dL)). Hypertension was defined as blood pressure (BP) levels of ≥ 140/90 mm Hg or use of BP lowering medications. Hypertension was observed among 3,467 participants (prevalence 46.3%). The prevalence of hypertension increased with elevation of serum uric acid levels: 42.8% in group 1, 55.0% in group 2, 57.6% in group 3 and 59.8% in group 4 (P < 0.001 for trend). This association was significant even after adjustment for other risk factors including age, sex, current smoking, current alcohol intake, obesity, diabetes, dyslipidemia, estimated glomerular filtration rate and proteinuria: odds ratios (95% confidence intervals) were 1.50 (1.28 - 1.77) for group 2, 1.58 (1.25 - 1.99) for group 3 and 1.89 (1.36 - 2.64) for group 4 compared with the reference group of group 1 (P < 0.001 for trend). Serum uric acid was clearly associated with prevalence of hypertension in a general population of Japanese.
Sections du résumé
BACKGROUND
BACKGROUND
There is uncertainty surrounding the causal relationship between serum uric acid and hypertension. The aim was to investigate the association between serum uric acid and prevalence of hypertension in a general population of Japanese.
METHODS
METHODS
This was a population-based cross-sectional study using health check-up data of the residents of the Iki City, Nagasaki Prefecture, Japan. A total of 7,484 participants aged 30 years or older were included in this study. Serum uric acid was classified into four groups: group 1 (< 357 µmol/L (< 6 mg/dL)), group 2 (357 - 415 µmol/L (6 - 6.9 mg/dL)), group 3 (416 - 475 µmol/L (7 - 7.9 mg/dL)) and group 4 (≥ 476 µmol/L (≥ 8 mg/dL)). Hypertension was defined as blood pressure (BP) levels of ≥ 140/90 mm Hg or use of BP lowering medications.
RESULTS
RESULTS
Hypertension was observed among 3,467 participants (prevalence 46.3%). The prevalence of hypertension increased with elevation of serum uric acid levels: 42.8% in group 1, 55.0% in group 2, 57.6% in group 3 and 59.8% in group 4 (P < 0.001 for trend). This association was significant even after adjustment for other risk factors including age, sex, current smoking, current alcohol intake, obesity, diabetes, dyslipidemia, estimated glomerular filtration rate and proteinuria: odds ratios (95% confidence intervals) were 1.50 (1.28 - 1.77) for group 2, 1.58 (1.25 - 1.99) for group 3 and 1.89 (1.36 - 2.64) for group 4 compared with the reference group of group 1 (P < 0.001 for trend).
CONCLUSIONS
CONCLUSIONS
Serum uric acid was clearly associated with prevalence of hypertension in a general population of Japanese.
Identifiants
pubmed: 32655737
doi: 10.14740/jocmr4171
pmc: PMC7331868
doi:
Types de publication
Journal Article
Langues
eng
Pagination
431-435Informations de copyright
Copyright 2020, Miyabayashi et al.
Déclaration de conflit d'intérêts
HA received research grants from Daiichi Sankyo and Takeda, lecture fees from Bayer, Daiichi Sankyo, Fukuda Denshi, MSD, Takeda, Teijin and fees for consultancy from Kyowa Kirin outside of the submitted work. There is no other conflict of interest.
Références
Intern Med. 2020 Jan 15;59(2):175-180
pubmed: 31554753
Clin Chem. 2009 Nov;55(11):2026-34
pubmed: 19729471
Hypertension. 2001 Nov;38(5):1101-6
pubmed: 11711505
Eur J Epidemiol. 2003;18(6):523-30
pubmed: 12908717
Kidney Int. 2005 Jan;67(1):237-47
pubmed: 15610247
J Hum Hypertens. 2019 Dec;33(12):873-878
pubmed: 31113986
J Hypertens. 2001 Jul;19(7):1209-15
pubmed: 11446710
PLoS One. 2014 Jun 24;9(6):e100801
pubmed: 24959886
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
Hypertens Res. 2019 Sep;42(9):1235-1481
pubmed: 31375757
BMJ. 2017 Jun 7;357:j2376
pubmed: 28592419
Hypertension. 2006 Dec;48(6):1037-42
pubmed: 17060502
Hypertension. 2002 Sep;40(3):355-60
pubmed: 12215479
Hypertens Res. 2004 Nov;27(11):835-41
pubmed: 15824465
Hypertension. 2007 Feb;49(2):298-303
pubmed: 17190877
J Hum Hypertens. 1999 Jan;13(1):13-21
pubmed: 9928747
Lancet. 2016 Aug 20;388(10046):761-75
pubmed: 27431356
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
PLoS One. 2014 Dec 01;9(12):e114259
pubmed: 25437867
Hypertension. 2005 Jan;45(1):28-33
pubmed: 15569852